Detalles de la búsqueda
1.
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.
Future Oncol
; 18(19): 2339-2349, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35465733
2.
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Breast Cancer Res
; 23(1): 38, 2021 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761970
3.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290610
4.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863451
5.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31949268
6.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32274665
7.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Lancet Oncol
; 20(3): 371-382, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30765258
8.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Breast Cancer Res
; 21(1): 71, 2019 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31142370
9.
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 120(10): 959-967, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30967649
10.
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Pharmacogenomics J
; 19(6): 556-563, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723313
11.
Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution.
Breast J
; 25(6): 1225-1229, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31310384
12.
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Lancet Oncol
; 19(10): 1385-1393, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30196031
13.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(1): 87-100, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29223745
14.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158011
15.
ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data.
BMC Genomics
; 19(1): 960, 2018 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30583719
16.
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Breast Cancer Res Treat
; 170(2): 329-341, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564743
17.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29589138
18.
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
BMC Cancer
; 18(1): 932, 2018 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30261866
19.
Using CTCs for pharmacogenomic analysis.
Pharmacol Res
; 106: 92-100, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26921662
20.
Metabolomics in Breast Cancer: Current Status and Perspectives.
Adv Exp Med Biol
; 882: 217-34, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26987537